• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Myasthenia gravis: the specificities of skeletal muscle and thymus antibodies.

作者信息

Gilhus N E, Aarli J A, Matre R

出版信息

Acta Neurol Scand. 1983 Nov;68(5):328-36. doi: 10.1111/j.1600-0404.1983.tb04840.x.

DOI:10.1111/j.1600-0404.1983.tb04840.x
PMID:6364682
Abstract

Antibodies against skeletal muscle antigens and against thymic myoid cells were examined in sera from 40 patients with myasthenia gravis (MG). Using an indirect immunofluorescence technique, antibodies against the surface of muscle cells were found in 23 sera, and antibodies against muscle cell cross-striations in 28 sera. Antibodies against thymic myoid cells were found in 27 sera, stained cells also occurring in fetal thymus from 14 weeks of gestation and in hyperplastic thymus from MG patients. Sera which stained myoid cells also stained muscle cell cross-striations. Sera from all the 20 patients with thymoma contained antibodies to a citric acid extract of skeletal muscle (CAE) as detected by indirect haemagglutination, whereas sera from 20 comparable patients without thymoma did not contain CAE antibodies. The myoid cell antibodies could be absorbed by homogenized muscle, but not by CAE-coated sheep erythrocytes. Different antibody patterns are seen among different MG patients; close associations were found between cross-striational and myoid cell antibodies, and between CAE-antibodies and a thymoma.

摘要

相似文献

1
Myasthenia gravis: the specificities of skeletal muscle and thymus antibodies.
Acta Neurol Scand. 1983 Nov;68(5):328-36. doi: 10.1111/j.1600-0404.1983.tb04840.x.
2
Myasthenia gravis. Antibodies to skeletal muscle cell surface antigens.重症肌无力。针对骨骼肌细胞表面抗原的抗体。
J Neuroimmunol. 1983 Dec;5(3):239-49. doi: 10.1016/0165-5728(83)90044-9.
3
Myasthenia gravis: difference between thymoma-associated antibodies and cross-striational skeletal muscle antibodies.重症肌无力:胸腺瘤相关抗体与横纹肌骨骼肌抗体的差异。
Neurology. 1984 Feb;34(2):246-9. doi: 10.1212/wnl.34.2.246.
4
Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymomas from myasthenia gravis patients.针对人骨骼肌柠檬酸提取物的兔抗血清可对重症肌无力患者的胸腺瘤进行染色。
J Neuroimmunol. 1984 Nov;7(1):55-64. doi: 10.1016/s0165-5728(84)80006-5.
5
[Detection of antibodies to citric acid extract of skeletal muscle (CAE-ab) in the sera of patients with myasthenia gravis using indirect hemagglutination].[应用间接血凝法检测重症肌无力患者血清中骨骼肌柠檬酸提取物抗体(CAE-ab)]
Zhonghua Shen Jing Jing Shen Ke Za Zhi. 1990 Jun;23(3):143-5, 189.
6
Skeletal muscle antibodies in patients with a thymic tumour but without myasthenia gravis.
J Neuroimmunol. 1985 May;8(2-3):69-78. doi: 10.1016/s0165-5728(85)80048-5.
7
Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination.通过间接血凝试验证实重症肌无力患者血清中的胸腺瘤特异性抗体。
J Neuroimmunol. 1981 Dec;1(4):421-7. doi: 10.1016/0165-5728(81)90021-7.
8
Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin.重症肌无力患者的胸腺B淋巴细胞克隆可分泌与肌球蛋白、α辅肌动蛋白或肌动蛋白发生反应的单克隆横纹肌自身抗体。
J Exp Med. 1986 Oct 1;164(4):1043-59. doi: 10.1084/jem.164.4.1043.
9
Antibodies to skeletal muscle in myasthenia gravis. Part 1. Diagnostic value for the detection of thymoma.重症肌无力患者骨骼肌抗体。第1部分。对胸腺瘤检测的诊断价值。
J Neurol Sci. 1993 Nov;119(2):183-8. doi: 10.1016/0022-510x(93)90132-i.
10
The reactivity of the antistriational antibodies associated with thymoma and myasthenia gravis.与胸腺瘤和重症肌无力相关的抗横纹肌抗体的反应性。
Clin Exp Immunol. 1977 Jan;27(1):66-73.

引用本文的文献

1
Muscle autoantibodies in myasthenia gravis: beyond diagnosis?重症肌无力中的肌肉自身抗体:超越诊断?
Expert Rev Clin Immunol. 2012 Jul;8(5):427-38. doi: 10.1586/eci.12.34.